TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1616253

Group type: EXPERIMENTAL
Intervention: Actapulgite
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 6437430

Group type: EXPERIMENTAL
Intervention: Mesna (2‐mercaptoethane sulphonate sodium)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Forced diuresis
Number of subjects: 61
Study: 3743860

Group type: EXPERIMENTAL
Intervention: Hydralazine alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hydralazine combined with pindolol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined therapy with hydralazine and pindolol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study: 31924631

Group type: COMPARATOR
Intervention: Intervention (not specified)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 226
Study: 29198305

Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nasal mask plus chinstrap (NM-CS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oronasal mask (ONM)
Number of subjects: 48
Study: 27955663

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 3g daily for 24 weeks
Number of subjects: 145

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 145
Study: 25048468

Group type: EXPERIMENTAL
Intervention: Grafix (human viable wound matrix)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard wound care (control)
Number of subjects: 97
Study: 22700161

Group type: EXPERIMENTAL
Intervention: Nortriptyline plus methylphenidate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo plus methylphenidate
Number of subjects: 43
Study: 21132128

Group type: EXPERIMENTAL
Intervention: Eating (light standard meal)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged supine position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fasting (control condition)
Number of subjects: 6
Study: 18640468

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% BID added to timolol maleate 0.5% BID
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% BID (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dorzolamide and timolol
Number of subjects: 40
Study: 15792398

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate (2 x 200 mg t.i.d.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ibuprofen arginate (2 x 200 mg t.i.d.)
Number of subjects: 38
Study: 12787013

Group type: EXPERIMENTAL
Intervention: Scalp cooling via gel cool caps
Number of subjects: 40

Group type: COMPARATOR
Intervention: No specific preventative intervention (Control)
Number of subjects: 40
Study: 10984365

Group type: EXPERIMENTAL
Intervention: Fluticasone (100 microg twice daily) for 7 days
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Fluticasone (100 microg twice daily) for 7 days in children with rhinovirus infection
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo for 7 days in children with rhinovirus infection
Number of subjects: 210
Study: 8771597

Group type: EXPERIMENTAL
Intervention: Gabapentin (Neurontin)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 1730841

Group type: EXPERIMENTAL
Intervention: Exercise Challenge (EC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control Studies
Number of subjects: 11
Study: 6486559

Group type: EXPERIMENTAL
Intervention: 400 mg of slow-release theophylline (TheoDur) twice a day
Number of subjects: 10
Study: 30270639

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACT) 1 g
Number of subjects: 16
Study: 29202655

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study: 27404031

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (1 mg/d, n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 44
Study: 24874565

Group type: EXPERIMENTAL
Intervention: 10 g oat bran
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10 g barley bran
Number of subjects: 42

Group type: COMPARATOR
Intervention: low fiber condition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ad libitum pizza lunch
Number of subjects: 42
Study: 22883013

Group type: EXPERIMENTAL
Intervention: VCu IUD
Number of subjects: 400

Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 400
Study: 21095280

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/d)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Eplerenone (50 mg/d)
Number of subjects: 107
Study: 18211446

Group type: EXPERIMENTAL
Intervention: Lidocaine (anaesthetic concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (anaesthetic concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine (anaesthetic concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine (analgesic concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (analgesic concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine (analgesic concentration)
Number of subjects: 0
Study: 16403053

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 192
Study: 14640055

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10781471

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl (0.03 mg/kg plus 2 microg/kg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Premedicated patients older than 60 yr
Number of subjects: 180
Study: 8787937

Group type: EXPERIMENTAL
Intervention: rhGH (0.4 U.kg‐1.week‐1) for 6 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rhGH (0.25 U.kg‐1.week‐1) for 24 months
Number of subjects: 16
Study: 1621247

Group type: EXPERIMENTAL
Intervention: 100 mg d-indobufen
Number of subjects: 10

Group type: COMPARATOR
Intervention: 200 mg dl-indobufen
Number of subjects: 10
Study: 3883734

Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30383438

Group type: EXPERIMENTAL
Intervention: HF educational board game conducted in Thai language
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care including standard education
Number of subjects: 76
Study: 30404622

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) in the active pill phase (20th to 21st day of OC cycle)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) in the inactive pill phase (2nd to 4th day of OC cycle)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Naturally cycling women (NCW) in the early follicular phase (4th - 5th days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Naturally cycling women (NCW) in the mid-luteal phase (20th-21st days)
Number of subjects: 51
Study: 27287206

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (180 μg subcutaneously 1×/week; 24 months)
Number of subjects: 909

Group type: COMPARATOR
Intervention: IFN α‐2a (3MIU subcutaneously 3×/week; 24 months)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: PEG‐IFN
Number of subjects: 909

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: PEG‐IFN and IFN
Number of subjects: 909
Study: 24135621

Group type: EXPERIMENTAL
Intervention: Spa treatment (balneotherapy) for 3 weeks, consisting of four sessions per day for 6 days a week.
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Spa treatment (balneotherapy) for 3 weeks.
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group received spa treatment after 1 year.
Number of subjects: 425
Study: 23451463

Group type: EXPERIMENTAL
Intervention: Nucleoplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 64
Study: 20087785

Group type: EXPERIMENTAL
Intervention: SLN positive patients with micrometastases (deposits < or =2 mm but >0.2 mm)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: SLN positive patients with macrometastases (deposits >2 mm)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: SLN positive patients with submicrometastases (deposits < or =0.2 mm)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Negative SLN patients
Number of subjects: 381
Study: 18385443

Group type: EXPERIMENTAL
Intervention: HerpeSelect assay
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Kalon assay
Number of subjects: 434
Study: 15823104

Group type: EXPERIMENTAL
Intervention: Vascular access ports (22 cases)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional vascular access (38 cases)
Number of subjects: 60
Study: 12479668

Group type: EXPERIMENTAL
Intervention: Oral loading dose of valproate (20 mg/kg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Slower titration dose of valproate (10 mg/kg/day)
Number of subjects: 11
Study: 10512897

Group type: EXPERIMENTAL
Intervention: Randomized trials of interventions for acute stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmaceutical industry involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially supported trials
Number of subjects: 0
Study: 8534459

Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 60
Study: 2333839

Group type: EXPERIMENTAL
Intervention: Corn oil-based diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-oleic acid sunflower oil-based diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Butter-based diet
Number of subjects: 20
Study: 389814

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: co‐trimazine
Number of subjects: 105

Group type: COMPARATOR
Intervention: sulphalene
Number of subjects: 105
Study: 31149842

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) for 24 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 27
Study: 28435501

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control group (no CDS)
Number of subjects: 613
Study: 24337500

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 119
Study: 23457080

Group type: EXPERIMENTAL
Intervention: Cephalexin plus trimethoprim-sulfamethoxazole
Number of subjects: 153

Group type: COMPARATOR
Intervention: Cephalexin alone (placebo group)
Number of subjects: 153
Study: 21353372

Group type: EXPERIMENTAL
Intervention: MVI 50 (misoprostol 50 mcg)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 1308
Study: 18582848

Group type: EXPERIMENTAL
Intervention: Memantine (maximum dose 20 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16861151

Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 101
Study: 14640255

Group type: EXPERIMENTAL
Intervention: Lipid lowering treatment
Number of subjects: 0
Study: 10828728

Group type: EXPERIMENTAL
Intervention: 0.5 mg ropinirole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9181161

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 56

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 56
Study: 8024107

Group type: EXPERIMENTAL
Intervention: Swimming group (unprotected water exposure)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Nonswimming group (no unprotected water exposure)
Number of subjects: 212
Study: 2684622

Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg/week r-hGH
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.0 IU/kg/week r-hGH
Number of subjects: 94

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 94
Study: 1035402

Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-nystatin (HNN)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hydrocortisone (HC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Iodochlorhydroxyquin-hydrocortisone (I-HC)
Number of subjects: 64
Study: 31302052

Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with SPRM score above median (n = 558)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: ICD implantation in patients with SPRM score below median (n = 558)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: ICD implantation in patients with SHFM score above median
Number of subjects: 1116

Group type: COMPARATOR
Intervention: ICD implantation in patients with SHFM score below median
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: ICD implantation in 177 patients with upper SPRM/upper SHFM
Number of subjects: 1116

Group type: COMPARATOR
Intervention: ICD implantation in 381 patients with lower SPRM/upper SHFM
Number of subjects: 1116
Study: 27835770

Group type: EXPERIMENTAL
Intervention: Eyeball exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Functional exercise
Number of subjects: 61
Study: 26066335

Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg daily for 6 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (soybean powder)
Number of subjects: 108
Study: 24476477

Group type: EXPERIMENTAL
Intervention: Curcumin 50 mg/kg daily for 8 weeks in DM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg daily for 12 weeks in obese humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcumin 750 mg daily for 12 weeks in obese humans
Number of subjects: 0
Study: 22503032

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 401

Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 401
Study: 19364302

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg once daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily plus Metformin 1000 mg once daily
Number of subjects: 17
Study: 17694726

Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study: 15580724

Group type: EXPERIMENTAL
Intervention: Physician Rapport and Partnership Building
Number of subjects: 140

Group type: COMPARATOR
Intervention: Information Giving
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Higher parent socioeconomic status
Number of subjects: 140
Study: 11729705

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline
Number of subjects: 0
Study: 9364979

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofibrate
Number of subjects: 0
Study: 1409483

Group type: EXPERIMENTAL
Intervention: Mammography adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pap test frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical breast exam frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast self-examination frequency
Number of subjects: 0
Study: 4028807

Group type: EXPERIMENTAL
Intervention: Slow-release tablet formulation of 300 mg fentiazac, given once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard tablet formulations of 100 mg, given 4-times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard tablet formulations of 200 mg, given twice daily
Number of subjects: 60
Study: 30758220

Group type: EXPERIMENTAL
Intervention: Question prompt list and educational video intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 359
Study: 29567321

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 48
Study: 26851696

Group type: COMPARATOR
Intervention: Bihemispheric tDCS (dual)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unihemispheric anodal tDCS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sham tDCS
Number of subjects: 24
Study: 24475777

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Fingolimod 1.25 mg or 0.5 mg (switched from placebo)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod (continuously treated)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod (in AQP4 antibody-positive patients)
Number of subjects: 143
Study: 22268125

Group type: EXPERIMENTAL
Intervention: Protandim (1,350 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protandim
Number of subjects: 30
Study: 20852750

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg tablet; LPH® S.C. LaborMed Pharma S.A. Romania)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zantac® (300 mg tablet; GlaxoSmithKline, Austria)
Number of subjects: 12
Study: 18180567

Group type: EXPERIMENTAL
Intervention: Na-hyaluronate (Orthovisc, n=38)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (Synvisc, n=18)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Streptococcal HA (Adant, n=21)
Number of subjects: 77
Study: 16303007

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg/day
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1652
Study: 12512229

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no eicosapentaenoic acid)
Number of subjects: 17
Study: 9809087

Group type: EXPERIMENTAL
Intervention: Thiopentone/fentanyl (Group 1: n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl (Group 2: n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both anaesthesia types (isoflurane and propofol)
Number of subjects: 32
Study: 7695972

Group type: EXPERIMENTAL
Intervention: rIL2/5‐FU/LV
Number of subjects: 135

Group type: COMPARATOR
Intervention: 5‐FU/LV
Number of subjects: 135
Study: 2316824

Group type: EXPERIMENTAL
Intervention: Dp-group (aluminium-hydroxide added to Dp-extract)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: mPEG-Dp-group (allergenicity reduced by coupling to mPEG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dp-group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: mPEG-Dp-group
Number of subjects: 37
Study: 7468956

Group type: EXPERIMENTAL
Intervention: Ketamine combined with halothane
Number of subjects: 48

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ethrane
Number of subjects: 48

Group type: COMPARATOR
Intervention: Halothane without ketamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ethrane without ketamine
Number of subjects: 48
Study: 31760911

Group type: EXPERIMENTAL
Intervention: Age- and dementia-relevant jury instructions
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Mock juror gender
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Implicit agism among jurors
Number of subjects: 391
Study: 31455707

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (72%)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Soft tissue therapy (70%)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Mobilisation (35%)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Back problems (49%, 95% CI 44 to 56)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Neck problems (15%, 95% CI 13 to 18)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Maintenance/preventive care (0.86%, 95% CI 0.2 to 3.9)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Non-musculoskeletal problems (1.3%, 95% CI 0.7 to 2.3)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Referrals from other patients (39.4%)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Referrals from physicians (6.8%)
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: Out of pocket or extended health insurance payments (68%)
Number of subjects: 3523
Study: 28450313

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 240
Study: 25967725

Group type: EXPERIMENTAL
Intervention: Low-dose selective spinal anesthesia with 5 mg bupivacaine + single‐shot femoral block with 0.25% bupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional dose selective spinal anesthesia with 10 mg bupivacaine
Number of subjects: 52
Study: 24045793

Group type: EXPERIMENTAL
Intervention: Fat (as the best performer ingredient from Study 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 different food ingredients (including coffee, tea, milk, curcumin, potato protease inhibitor)
Number of subjects: 29
Study: 21863030

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (320 mg day(-1))
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 204
Study: 19549707

Group type: EXPERIMENTAL
Intervention: CET-CF (cetuximab plus cisplatin-5-fluorouracil); cetuximab 400 mg/m² initial dose followed by 250 mg/m² weekly, cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Number of subjects: 62

Group type: COMPARATOR
Intervention: CF (cisplatin-5-fluorouracil); cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Number of subjects: 62
Study: 17547268

Group type: EXPERIMENTAL
Intervention: Consumption of hot and cold beverages; waiting at least 30 minutes after drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bradypnea
Number of subjects: 0